67% of additional patients (n=6) enrolled in the BEACON study achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points 75% of CSU participants (n=36) enrolled in the open...
Thomas Wiggans appointed Executive Chairperson Jasper to host an investor webinar on January 8 th at 8:00am ET to present updated data from the BEACON study in CSU and the open-label extension...
Reductions in airway hyperresponsiveness and suppressed eosinophilic response at both 6 weeks and 12 weeks observed after a single 180mg dose of Briquilimab in the ETESIAN Study Preliminary data from...
REDWOOD CITY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper or the Company), a clinical stage biotechnology company focused on development of briquilimab,...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Jasper To Contact Him Directly To Discuss Their Options...
The Law Offices of Frank R. Cruz reminds investors of the upcoming November 18, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed...
NEW YORK , Nov. 14, 2025 /PRNewswire/ --Â
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Jasper To Contact Him Directly To Discuss Their Options
LOS ANGELES , Nov. 14, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Jasper Therapeutics,...
LOS ANGELES , Nov. 14, 2025 /PRNewswire/ -- The DJS Law Group  reminds investors of a class action lawsuit against Jasper Therapeutics, Inc. ("Jasper" or "the Company") (NASDAQ: JSPR ) for...